dda1 Search Results


dda1  (OriGene)
90
OriGene dda1
Dda1, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dda1/product/OriGene
Average 90 stars, based on 1 article reviews
dda1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dda1  (Proteintech)
93
Proteintech dda1
(A) Schema of experimental design. (B) Quantification of bioluminescence emitted by H2030-BrM established metastases in brain organotypic cultures. BLI values were obtained 6h after the addition of DEBIO-0932 or DMSO normalized by the values of each culture before any treatment. Data is shown as relative to DMSO BLI values in box-and-whisker plots where every dot represents an organotypic culture and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=20 organotypic cultures per experimental condition, 3 independent experiments). P value was calculated using two-tailed t-test. (C) Representative image of a fully established brain metastasis from H2030-BrM before and after laser capture microdissection (LCM). The dotted line delimits the metastasis. Scale bar, 100 μm. (D) Volcano plot with deregulated proteins (red: upregulated; green: downregulated) found in brain metastases treated with DEBIO-0932 compared to DMSO (n=3 biological replicates (mice) per condition, n≥12 brain metastases per mouse were pooled together). Proteins with a P value <0.05 and a log 2 ratio >1 or <-1 were defined as deregulated. Gray dotted lines indicate P value and log2 ratio cut offs. The names of the top deregulated proteins are shown. (E) Representative images showing RPLP1, AHR, UBE4B and <t>DDA1</t> levels in brain metastases (generated by intracardiac inoculation of H2030-BrM) found at endpoint of vehicle and DEBIO-0932 treated animals. This result was reproduced in 2 independent staining with different brains. BB: bisbenzamide. Scale bars, 50 μm; high magnification, 12 μm. (F) Quantification of percentage of nuclear DDA1+ BB+ cells shown in (E). Values are shown in box-and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=16 metastatic lesions from 4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (G) Quantification of RPLP1 and AHR levels shown in (E) in arbitrary fluorescent units (A.F.U.). Values are shown in box- and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=8-16 metastatic lesions from 2-4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (H) GSEA of top 25 upregulated (red) and downregulated (green; only four fulfill the filter) pathways upon DEBIO-0932 treatment. Those biological processes represented with more than one signature are labelled with colored lines. (I) Examples of signatures included in the main biological processes represented in the proteomic analysis. GO:0000981 corresponds to the Gene Ontology signature “DNA binding, Transcription factor activity, RNA polymerase II specific”. (J) Representative images showing p-ERK levels in organotypic cultures from (B). This result was reproduced in 3 independent staining with organotypic cultures from different mice. Scale bar, 20 μm. (K) Immunohistochemistry against UBE4B and AHR in 16 human brain metastases with (green) and without (red) HSP90-dependent oncogenic drivers. No molecular information available for the sample depicted in gray. Scale bar, 50 μm. (L) Kaplan-Meier curves showing significant correlation between worse survival post-brain metastasis (SPBM) and high expression levels of UBE4B (upper panel) or DDA1 (lower panel) in a cohort of 21 breast cancer brain metastasis patients.
Dda1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dda1/product/Proteintech
Average 93 stars, based on 1 article reviews
dda1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
full-length expression construct with gfp-dda1 and gfp-dda1 δ  (GenScript corporation)
90
GenScript corporation full-length expression construct with gfp-dda1 and gfp-dda1 δ
(A) Schema of experimental design. (B) Quantification of bioluminescence emitted by H2030-BrM established metastases in brain organotypic cultures. BLI values were obtained 6h after the addition of DEBIO-0932 or DMSO normalized by the values of each culture before any treatment. Data is shown as relative to DMSO BLI values in box-and-whisker plots where every dot represents an organotypic culture and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=20 organotypic cultures per experimental condition, 3 independent experiments). P value was calculated using two-tailed t-test. (C) Representative image of a fully established brain metastasis from H2030-BrM before and after laser capture microdissection (LCM). The dotted line delimits the metastasis. Scale bar, 100 μm. (D) Volcano plot with deregulated proteins (red: upregulated; green: downregulated) found in brain metastases treated with DEBIO-0932 compared to DMSO (n=3 biological replicates (mice) per condition, n≥12 brain metastases per mouse were pooled together). Proteins with a P value <0.05 and a log 2 ratio >1 or <-1 were defined as deregulated. Gray dotted lines indicate P value and log2 ratio cut offs. The names of the top deregulated proteins are shown. (E) Representative images showing RPLP1, AHR, UBE4B and <t>DDA1</t> levels in brain metastases (generated by intracardiac inoculation of H2030-BrM) found at endpoint of vehicle and DEBIO-0932 treated animals. This result was reproduced in 2 independent staining with different brains. BB: bisbenzamide. Scale bars, 50 μm; high magnification, 12 μm. (F) Quantification of percentage of nuclear DDA1+ BB+ cells shown in (E). Values are shown in box-and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=16 metastatic lesions from 4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (G) Quantification of RPLP1 and AHR levels shown in (E) in arbitrary fluorescent units (A.F.U.). Values are shown in box- and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=8-16 metastatic lesions from 2-4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (H) GSEA of top 25 upregulated (red) and downregulated (green; only four fulfill the filter) pathways upon DEBIO-0932 treatment. Those biological processes represented with more than one signature are labelled with colored lines. (I) Examples of signatures included in the main biological processes represented in the proteomic analysis. GO:0000981 corresponds to the Gene Ontology signature “DNA binding, Transcription factor activity, RNA polymerase II specific”. (J) Representative images showing p-ERK levels in organotypic cultures from (B). This result was reproduced in 3 independent staining with organotypic cultures from different mice. Scale bar, 20 μm. (K) Immunohistochemistry against UBE4B and AHR in 16 human brain metastases with (green) and without (red) HSP90-dependent oncogenic drivers. No molecular information available for the sample depicted in gray. Scale bar, 50 μm. (L) Kaplan-Meier curves showing significant correlation between worse survival post-brain metastasis (SPBM) and high expression levels of UBE4B (upper panel) or DDA1 (lower panel) in a cohort of 21 breast cancer brain metastasis patients.
Full Length Expression Construct With Gfp Dda1 And Gfp Dda1 δ, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/full-length expression construct with gfp-dda1 and gfp-dda1 δ/product/GenScript corporation
Average 90 stars, based on 1 article reviews
full-length expression construct with gfp-dda1 and gfp-dda1 δ - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti-dda1  (WuXi AppTec)
90
WuXi AppTec anti-dda1
(A) Schema of experimental design. (B) Quantification of bioluminescence emitted by H2030-BrM established metastases in brain organotypic cultures. BLI values were obtained 6h after the addition of DEBIO-0932 or DMSO normalized by the values of each culture before any treatment. Data is shown as relative to DMSO BLI values in box-and-whisker plots where every dot represents an organotypic culture and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=20 organotypic cultures per experimental condition, 3 independent experiments). P value was calculated using two-tailed t-test. (C) Representative image of a fully established brain metastasis from H2030-BrM before and after laser capture microdissection (LCM). The dotted line delimits the metastasis. Scale bar, 100 μm. (D) Volcano plot with deregulated proteins (red: upregulated; green: downregulated) found in brain metastases treated with DEBIO-0932 compared to DMSO (n=3 biological replicates (mice) per condition, n≥12 brain metastases per mouse were pooled together). Proteins with a P value <0.05 and a log 2 ratio >1 or <-1 were defined as deregulated. Gray dotted lines indicate P value and log2 ratio cut offs. The names of the top deregulated proteins are shown. (E) Representative images showing RPLP1, AHR, UBE4B and <t>DDA1</t> levels in brain metastases (generated by intracardiac inoculation of H2030-BrM) found at endpoint of vehicle and DEBIO-0932 treated animals. This result was reproduced in 2 independent staining with different brains. BB: bisbenzamide. Scale bars, 50 μm; high magnification, 12 μm. (F) Quantification of percentage of nuclear DDA1+ BB+ cells shown in (E). Values are shown in box-and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=16 metastatic lesions from 4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (G) Quantification of RPLP1 and AHR levels shown in (E) in arbitrary fluorescent units (A.F.U.). Values are shown in box- and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=8-16 metastatic lesions from 2-4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (H) GSEA of top 25 upregulated (red) and downregulated (green; only four fulfill the filter) pathways upon DEBIO-0932 treatment. Those biological processes represented with more than one signature are labelled with colored lines. (I) Examples of signatures included in the main biological processes represented in the proteomic analysis. GO:0000981 corresponds to the Gene Ontology signature “DNA binding, Transcription factor activity, RNA polymerase II specific”. (J) Representative images showing p-ERK levels in organotypic cultures from (B). This result was reproduced in 3 independent staining with organotypic cultures from different mice. Scale bar, 20 μm. (K) Immunohistochemistry against UBE4B and AHR in 16 human brain metastases with (green) and without (red) HSP90-dependent oncogenic drivers. No molecular information available for the sample depicted in gray. Scale bar, 50 μm. (L) Kaplan-Meier curves showing significant correlation between worse survival post-brain metastasis (SPBM) and high expression levels of UBE4B (upper panel) or DDA1 (lower panel) in a cohort of 21 breast cancer brain metastasis patients.
Anti Dda1, supplied by WuXi AppTec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-dda1/product/WuXi AppTec
Average 90 stars, based on 1 article reviews
anti-dda1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
gel-dda (1:1)  (CH Instruments)
90
CH Instruments gel-dda (1:1)
(A) Schema of experimental design. (B) Quantification of bioluminescence emitted by H2030-BrM established metastases in brain organotypic cultures. BLI values were obtained 6h after the addition of DEBIO-0932 or DMSO normalized by the values of each culture before any treatment. Data is shown as relative to DMSO BLI values in box-and-whisker plots where every dot represents an organotypic culture and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=20 organotypic cultures per experimental condition, 3 independent experiments). P value was calculated using two-tailed t-test. (C) Representative image of a fully established brain metastasis from H2030-BrM before and after laser capture microdissection (LCM). The dotted line delimits the metastasis. Scale bar, 100 μm. (D) Volcano plot with deregulated proteins (red: upregulated; green: downregulated) found in brain metastases treated with DEBIO-0932 compared to DMSO (n=3 biological replicates (mice) per condition, n≥12 brain metastases per mouse were pooled together). Proteins with a P value <0.05 and a log 2 ratio >1 or <-1 were defined as deregulated. Gray dotted lines indicate P value and log2 ratio cut offs. The names of the top deregulated proteins are shown. (E) Representative images showing RPLP1, AHR, UBE4B and <t>DDA1</t> levels in brain metastases (generated by intracardiac inoculation of H2030-BrM) found at endpoint of vehicle and DEBIO-0932 treated animals. This result was reproduced in 2 independent staining with different brains. BB: bisbenzamide. Scale bars, 50 μm; high magnification, 12 μm. (F) Quantification of percentage of nuclear DDA1+ BB+ cells shown in (E). Values are shown in box-and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=16 metastatic lesions from 4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (G) Quantification of RPLP1 and AHR levels shown in (E) in arbitrary fluorescent units (A.F.U.). Values are shown in box- and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=8-16 metastatic lesions from 2-4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (H) GSEA of top 25 upregulated (red) and downregulated (green; only four fulfill the filter) pathways upon DEBIO-0932 treatment. Those biological processes represented with more than one signature are labelled with colored lines. (I) Examples of signatures included in the main biological processes represented in the proteomic analysis. GO:0000981 corresponds to the Gene Ontology signature “DNA binding, Transcription factor activity, RNA polymerase II specific”. (J) Representative images showing p-ERK levels in organotypic cultures from (B). This result was reproduced in 3 independent staining with organotypic cultures from different mice. Scale bar, 20 μm. (K) Immunohistochemistry against UBE4B and AHR in 16 human brain metastases with (green) and without (red) HSP90-dependent oncogenic drivers. No molecular information available for the sample depicted in gray. Scale bar, 50 μm. (L) Kaplan-Meier curves showing significant correlation between worse survival post-brain metastasis (SPBM) and high expression levels of UBE4B (upper panel) or DDA1 (lower panel) in a cohort of 21 breast cancer brain metastasis patients.
Gel Dda (1:1), supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gel-dda (1:1)/product/CH Instruments
Average 90 stars, based on 1 article reviews
gel-dda (1:1) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A) Schema of experimental design. (B) Quantification of bioluminescence emitted by H2030-BrM established metastases in brain organotypic cultures. BLI values were obtained 6h after the addition of DEBIO-0932 or DMSO normalized by the values of each culture before any treatment. Data is shown as relative to DMSO BLI values in box-and-whisker plots where every dot represents an organotypic culture and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=20 organotypic cultures per experimental condition, 3 independent experiments). P value was calculated using two-tailed t-test. (C) Representative image of a fully established brain metastasis from H2030-BrM before and after laser capture microdissection (LCM). The dotted line delimits the metastasis. Scale bar, 100 μm. (D) Volcano plot with deregulated proteins (red: upregulated; green: downregulated) found in brain metastases treated with DEBIO-0932 compared to DMSO (n=3 biological replicates (mice) per condition, n≥12 brain metastases per mouse were pooled together). Proteins with a P value <0.05 and a log 2 ratio >1 or <-1 were defined as deregulated. Gray dotted lines indicate P value and log2 ratio cut offs. The names of the top deregulated proteins are shown. (E) Representative images showing RPLP1, AHR, UBE4B and DDA1 levels in brain metastases (generated by intracardiac inoculation of H2030-BrM) found at endpoint of vehicle and DEBIO-0932 treated animals. This result was reproduced in 2 independent staining with different brains. BB: bisbenzamide. Scale bars, 50 μm; high magnification, 12 μm. (F) Quantification of percentage of nuclear DDA1+ BB+ cells shown in (E). Values are shown in box-and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=16 metastatic lesions from 4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (G) Quantification of RPLP1 and AHR levels shown in (E) in arbitrary fluorescent units (A.F.U.). Values are shown in box- and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=8-16 metastatic lesions from 2-4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (H) GSEA of top 25 upregulated (red) and downregulated (green; only four fulfill the filter) pathways upon DEBIO-0932 treatment. Those biological processes represented with more than one signature are labelled with colored lines. (I) Examples of signatures included in the main biological processes represented in the proteomic analysis. GO:0000981 corresponds to the Gene Ontology signature “DNA binding, Transcription factor activity, RNA polymerase II specific”. (J) Representative images showing p-ERK levels in organotypic cultures from (B). This result was reproduced in 3 independent staining with organotypic cultures from different mice. Scale bar, 20 μm. (K) Immunohistochemistry against UBE4B and AHR in 16 human brain metastases with (green) and without (red) HSP90-dependent oncogenic drivers. No molecular information available for the sample depicted in gray. Scale bar, 50 μm. (L) Kaplan-Meier curves showing significant correlation between worse survival post-brain metastasis (SPBM) and high expression levels of UBE4B (upper panel) or DDA1 (lower panel) in a cohort of 21 breast cancer brain metastasis patients.

Journal: bioRxiv

Article Title: A drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent local relapse and treat established brain metastasis

doi: 10.1101/2020.10.16.329243

Figure Lengend Snippet: (A) Schema of experimental design. (B) Quantification of bioluminescence emitted by H2030-BrM established metastases in brain organotypic cultures. BLI values were obtained 6h after the addition of DEBIO-0932 or DMSO normalized by the values of each culture before any treatment. Data is shown as relative to DMSO BLI values in box-and-whisker plots where every dot represents an organotypic culture and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=20 organotypic cultures per experimental condition, 3 independent experiments). P value was calculated using two-tailed t-test. (C) Representative image of a fully established brain metastasis from H2030-BrM before and after laser capture microdissection (LCM). The dotted line delimits the metastasis. Scale bar, 100 μm. (D) Volcano plot with deregulated proteins (red: upregulated; green: downregulated) found in brain metastases treated with DEBIO-0932 compared to DMSO (n=3 biological replicates (mice) per condition, n≥12 brain metastases per mouse were pooled together). Proteins with a P value <0.05 and a log 2 ratio >1 or <-1 were defined as deregulated. Gray dotted lines indicate P value and log2 ratio cut offs. The names of the top deregulated proteins are shown. (E) Representative images showing RPLP1, AHR, UBE4B and DDA1 levels in brain metastases (generated by intracardiac inoculation of H2030-BrM) found at endpoint of vehicle and DEBIO-0932 treated animals. This result was reproduced in 2 independent staining with different brains. BB: bisbenzamide. Scale bars, 50 μm; high magnification, 12 μm. (F) Quantification of percentage of nuclear DDA1+ BB+ cells shown in (E). Values are shown in box-and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=16 metastatic lesions from 4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (G) Quantification of RPLP1 and AHR levels shown in (E) in arbitrary fluorescent units (A.F.U.). Values are shown in box- and-whisker plots where each dot is a metastatic lesion and the line in the box corresponds to the median. Whiskers go from the minimum to the maximum value (n=8-16 metastatic lesions from 2-4 brains per condition, 2 independent staining with different brains were performed). P value was calculated using two-tailed t-test. (H) GSEA of top 25 upregulated (red) and downregulated (green; only four fulfill the filter) pathways upon DEBIO-0932 treatment. Those biological processes represented with more than one signature are labelled with colored lines. (I) Examples of signatures included in the main biological processes represented in the proteomic analysis. GO:0000981 corresponds to the Gene Ontology signature “DNA binding, Transcription factor activity, RNA polymerase II specific”. (J) Representative images showing p-ERK levels in organotypic cultures from (B). This result was reproduced in 3 independent staining with organotypic cultures from different mice. Scale bar, 20 μm. (K) Immunohistochemistry against UBE4B and AHR in 16 human brain metastases with (green) and without (red) HSP90-dependent oncogenic drivers. No molecular information available for the sample depicted in gray. Scale bar, 50 μm. (L) Kaplan-Meier curves showing significant correlation between worse survival post-brain metastasis (SPBM) and high expression levels of UBE4B (upper panel) or DDA1 (lower panel) in a cohort of 21 breast cancer brain metastasis patients.

Article Snippet: Primary antibodies: GFP (1:1,000; GFP-1020, Aves Labs), BrdU (1:500; ab6326, Abcam), Ki67 (1:500; ab15580, Abcam), HSP90α/β F-8 (1:500; sc-13119; Santa Cruz Biotechnology), HSP70/ HSC70 W27 (1:500; sc-24; Santa Cruz Biotechnology), AHR (1:300; 31.714.200, US Biological), UBE4B (1:100; ab97697; Abcam), RPLP1 (1:100; HPA003368, Sigma-Aldrich), DDA1 (1:100; 14995-1-AP; ProteinTech), NeuN (1:500; MAB377, Millipore), collagen IV (1:1000; AB756P, Millipore).

Techniques: Whisker Assay, Two Tailed Test, Laser Capture Microdissection, Generated, Staining, Binding Assay, Activity Assay, Immunohistochemistry, Expressing